Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
291 Leser
Artikel bewerten:
(1)

Zach Crane Joins Twin Vee PowerCats Co. as Director of National Sales

Finanznachrichten News

FORT PIERCE, FL / ACCESSWIRE / October 25, 2022 / Twin Vee PowerCats, Co. (NASDAQ:VEEE), ("Twin Vee" or the "Company"), a manufacturer, distributor, and marketer of power sport catamaran boats, today announced that it has hired industry veteran Zachary Crane as its Director of National Sales to support its continued growth and enhance its presence in key national markets and other territories. Mr. Crane's new position is effective immediately.

"As Director of National Sales, Zach will play a crucial role in recruiting, leading, and supporting new Twin Vee dealers in all new territories," says Joseph Visconti, CEO and President of Twin Vee PowerCats Co. "An incredibly strong background in recreational marine sales gives Zach unique insights into the challenges and opportunities facing our industry. Additionally, we believe his established relationships with dealers across the country will allow him to hit the ground running and continue the great momentum Twin Vee has built."

Mr. Crane shares Visconti's excitement and looks forward to collaborating with the Twin Vee team with the intention to open new markets and expand distribution. "Great things in business are never done by one person. They are done by a team of people," states Crane.

Zachary Crane joins Twin Vee with over 13 years of experience in the marine industry. Most recently, Mr. Crane worked for Malibu Boats in Northeast Regional Sales, where he focused on dealer development and distribution for new and current dealer on behalf of Cobia, Maverick, Pathfinder, Hewes and Pursuit Boat brands. He also spent five years as an independent sales representative servicing over 40 dealers for Maverick Boat Group and Bentley Pontoon Boats as well as 38 dealers for Crownline Boats and Crest Pontoon Boats. From 2011 to 2016, Mr. Crane was a yacht consultant and received several elite and top sales awards at C-JAM Yacht Sales in Somers Point, New Jersey. Additionally, he worked in brokerage sales and boat sales at Jersey Marine in Somers Point, New Jersey from 2009 to 2011.

Mr. Crane graduated with a Bachelor of Science from Jacksonville University in June 2010.

About Twin Vee PowerCats Co.

Twin Vee PowerCats Co. has designed, built, and sold recreational power sport catamaran boats for over 27 years. Twin Vee's hull designs and engineering has placed the company on the leading edge of marine innovation. Twin Vee boats are known as "Best Riding Boats on the Water" because catamarans reduce drag, increase fuel efficiency, and offer boaters a more stable riding boat. Located in Fort Pierce Florida, Twin Vee's facility is 7.5-acres with several buildings totaling over 75,000 square feet. The Company currently employs approximately 180 people. Learn more at twinvee.com.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" and similar expressions that are intended to identify forward-looking statements and include statements regarding the expected contribution of Mr. Crane and continuing the great momentum Twin Vee has built. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, Mr. Crane's ability to recruit, lead, and support new Twin Vee dealers in new territories, Mr. Crane's ability to leverage his established relationships with dealers across the country to continue the momentum Twin Vee has built, the duration and scope of the COVID-19 outbreak worldwide, including the impact to supply chains and state and local economies, and the risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, the Company's Quarterly Reports on Form 10-Q, the Company's Current Reports on Form 8-K and subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events, except as required by law.

All product names referenced herein are trademarks of their respective companies.

Contact:
Glenn Sonoda
investor@twinvee.com

SOURCE: Twin Vee PowerCats Co.

View source version on accesswire.com:
https://www.accesswire.com/721977/Zach-Crane-Joins-Twin-Vee-PowerCats-Co-as-Director-of-National-Sales

© 2022 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.